Internal Medicine

nagao ryunosuke

  (長尾 龍之介)

Profile Information

Affiliation
School of Medicine Faculty of Medicine , Fujita Health University
Degree
学士(医学)(藤田保健衛生大学)

J-GLOBAL ID
201601015306998227
researchmap Member ID
7000015585

Papers

 80
  • Sayuri Shima, Yasuaki Mizutani, Junichiro Yoshimoto, Yasuhiro Maeda, Reiko Ohdake, Ryunosuke Nagao, Toshiki Maeda, Atsuhiro Higashi, Akihiro Ueda, Mizuki Ito, Tatsuro Mutoh, Hirohisa Watanabe
    NPJ Parkinson's disease, 10(1) 170-170, Sep 9, 2024  
    The relationship between reduced serum uric acid (UA) levels and Parkinson's disease (PD), particularly purine metabolic pathways, is not fully understood. Our study compared serum and cerebrospinal fluid (CSF) levels of inosine, hypoxanthine, xanthine, and UA in PD patients and healthy controls. We analyzed 132 samples (serum, 45 PD, and 29 age- and sex-matched healthy controls; CSF, 39 PD, and 19 age- and sex-matched healthy controls) using liquid chromatography-tandem mass spectrometry. Results showed significantly lower serum and CSF UA levels in PD patients than in controls (p < 0.0001; effect size r = 0.5007 in serum, p = 0.0046; r = 0.3720 in CSF). Decreased serum hypoxanthine levels were observed (p = 0.0002; r = 0.4338) in PD patients compared to controls with decreased CSF inosine and hypoxanthine levels (p < 0.0001, r = 0.5396: p = 0.0276, r = 0.2893). A general linear model analysis indicated that the reduced UA levels were mainly due to external factors such as sex and weight in serum and age and weight in CSF unrelated to the purine metabolic pathway. Our findings highlight that decreased UA levels in PD are influenced by factors beyond purine metabolism, including external factors such as sex, weight, and age, emphasizing the need for further research into the underlying mechanisms and potential therapeutic approaches.
  • Ryunosuke Nagao, Yasuaki Mizutani, Sayuri Shima, Akihiro Ueda, Mizuki Ito, Junichiro Yoshimoto, Hirohisa Watanabe
    European journal of neurology, 31(3) e16158, Mar, 2024  
    BACKGROUND AND PURPOSE: Multiple system atrophy (MSA) is a neurodegenerative disease with characteristic motor and autonomic symptoms. Impaired brain serotonergic innervation can be associated with various clinical indices of MSA; however, the relationship between clinical symptoms and cerebrospinal fluid (CSF) levels of 5-hydroxyindole acetic acid (5-HIAA), a main serotonin metabolite, has not been fully elucidated. METHODS: To compare CSF 5-HIAA levels between patients with MSA and healthy controls, we included 33 controls and 69 MSA patients with either predominant parkinsonian or cerebellar ataxia subtypes. CSF 5-HIAA levels were measured using high-performance liquid chromatography. Additionally, we investigated correlations between CSF 5-HIAA and various clinical indices in 34 MSA patients. RESULTS: CSF 5-HIAA levels were significantly lower in MSA patients than in controls (p < 0.0001). Probable MSA patients had lower CSF 5-HIAA levels than possible MSA patients (p < 0.001). In MSA patients, CSF 5-HIAA levels were inversely correlated with scores in Parts 1, 2, and 4 of the Unified Multiple System Atrophy Rating Scale, and with systolic and diastolic blood pressure in Part 3. Structural equation modeling revealed significant paths between serotonin and clinical symptoms, and significance was highest for activities of daily living, walking, and body sway. CONCLUSIONS: Serotonin dysfunction, as assessed by CSF 5-HIAA levels, may implicate greater MSA severity.
  • 安達 隼輔, 大嶽 れい子, 建部 陽嗣, 東 篤宏, 長尾 龍之介, 前田 利樹, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 徳田 隆彦, 渡辺 宏久
    パーキンソン病・運動障害疾患コングレスプログラム・抄録集, 17回 91-91, Jul, 2023  
  • 神田 好加, 大嶽 れい子, 安達 隼輔, 河野 洋介, 辻村 優次, 中野 頌子, 林 和孝, 加藤 邦尚, 坂野 文彦, 菊池 洸一, 東 篤宏, 長尾 龍之介, 前田 利樹, 廣田 政古, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 渡辺 宏久
    パーキンソン病・運動障害疾患コングレスプログラム・抄録集, 17回 109-109, Jul, 2023  
  • 水谷 泰彰, 大嶽 れい子, 前田 康博, 東 篤宏, 前田 利樹, 長尾 龍之介, 島 さゆり, 植田 晃広, 渡辺 宏久
    パーキンソン病・運動障害疾患コングレスプログラム・抄録集, 17回 109-109, Jul, 2023  

Misc.

 39
  • 中野 頌子, 林 和孝, 坂野 文彦, 加藤 邦尚, 東 篤宏, 菊池 洸一, 長尾 龍之介, 前田 利樹, 村手 健一郎, 廣田 政古, 石川 等真, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 武藤 多津郎, 渡辺 宏久
    臨床神経学, 61(11) 769-769, Nov, 2021  
  • 村手 健一郎, 中野 頌子, 林 和孝, 坂野 文彦, 加藤 邦尚, 東 篤宏, 菊池 洸一, 長尾 龍之介, 前田 利樹, 廣田 政古, 石川 等真, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 渡辺 宏久, 小池 春樹, 勝野 雅央
    臨床神経学, 61(11) 790-790, Nov, 2021  
  • Akihiro Ueda, Mayumi Senda, Kunihisa Kato, Syunske Adachi, Konoka Esaka, Yuji Tsujimura, Syuko Nakano, Kazutaka Hayashi, Fumihiko Banno, Koichi Kikuchi, Atsuhiro Higashi, Ryunosuke Nagao, Toshiki Maeda, Tetsuharu Kako, Seiko Hirota, Tomomasa Ishikawa, Yasuaki Mizutani, Sayuri Shima, Mizuki Ito, Shinji Ito, Tatsuro Mutoh, Hirohisa Watanabe
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 429, Oct, 2021  
  • 東 篤宏, 中野 頌子, 林 和孝, 加藤 邦尚, 坂野 文彦, 菊池 洸一, 前田 利樹, 長尾 龍之介, 村手 健一郎, 廣田 政古, 石川 等真, 水谷 泰彰, 島 さゆり, 伊藤 瑞規, 植田 晃広, 渡辺 宏久
    臨床神経学, 61(Suppl.) S256-S256, Sep, 2021  
  • 林 和孝, 中野 頌子, 坂野 文彦, 加藤 邦尚, 東 篤宏, 菊池 洸一, 前田 利樹, 長尾 龍之介, 村手 健一郎, 石川 等真, 廣田 政古, 水谷 泰彰, 島 さゆり, 植田 晃広, 伊藤 瑞規, 伊藤 信二, 武藤 多津郎, 渡辺 宏久
    臨床神経学, 61(Suppl.) S229-S229, Sep, 2021  

Presentations

 7